Ensign Group (ENSG) is under pressure after short seller reports accusing the company of falsifying care quality data, understaffing facilities, and engaging in improper billing practices. These reports have triggered multiple securities law investigations.

At a share price of $168.22, Ensign Group has experienced short-term share price pressure, with a 90-day share price return that declined 14.44%, while its 1-year total shareholder return is 12.18% and 3-year total shareholder return is 89.97%. This indicates that longer-term investors have had a different experience compared with more recent buyers.

If the allegations and index reshuffling have you reassessing your watchlist, it can help to see how other healthcare operators are being priced and perceived through a focused screener like 40 healthcare AI stocks

So with Ensign Group trading at $168.22, sitting close to an estimated intrinsic value and at a discount to some analyst targets, are you looking at a genuine mispricing here, or is the market already accounting for future growth?

Price-to-Earnings of 26.8x: Is it justified?

On a P/E of 26.8x, Ensign Group trades at a higher earnings multiple than both the broader US Healthcare sector and its own peer set, even after the recent share price pullback.

The P/E ratio shows how much investors are paying today for each dollar of Ensign Group’s earnings. For healthcare operators, this is a common shorthand for how the market is weighing current profits against expected future earnings growth and business quality.

Here, the market is pricing Ensign Group at 26.8x earnings, compared with 25.6x for the US Healthcare industry and 15.8x for its immediate peer average. That is a clear premium. At the same time, Simply Wall St’s fair P/E estimate for the stock sits at 25.2x, which is lower than where the shares trade today and suggests a level the market could move toward if expectations cool.

Result: Price-to-Earnings of 26.8x (OVERVALUED)

However, for Ensign Group, the short seller allegations and ongoing securities law investigations could still pressure sentiment and challenge assumptions embedded in that premium P/E ratio.

Another View on Ensign Group’s Value

While Ensign Group screens as expensive on a P/E of 26.8x, the SWS DCF model points to a different outcome, with the stock trading at $168.22 versus an estimated future cash flow value of $169.63. That is a small 0.8% gap. Is the real risk that expectations are simply very tight here?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ensign Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 43 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals around Ensign Group leave you unsure, it makes sense to move quickly, review the full picture, and shape your own view using 4 key rewards

Looking for more investment ideas beyond Ensign Group?

If Ensign Group has sharpened your focus, do not stop here. Broaden your watchlist with other stocks that match clear financial and return objectives.

• Target steadier compounding by reviewing 43 high quality undervalued stocks that combine quality fundamentals with room for the market to re-rate them.
• Build income resilience by scanning 7 dividend fortresses that aim to pair higher yields with more robust profiles.
• Prioritise capital protection first by focusing on 75 resilient stocks with low risk scores that score better on balance sheet strength and risk checks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.